Company intelligence / Profile preview
Roivant Sciences
New York City, New York, United Statesroivant.com ↗
- Ownership
- Public · ROIV
- Employees
- ~950
- Development stage
- Other
01
Overview
Since its founding in 2014, Roivant has achieved ten positive Phase III trials since 2019 and eight FDA approvals through its Vant companies. Its first commercial launch was VTAMA® cream in plaque psoriasis. The company continues to advance a broad pipeline spanning multiple therapeutic areas with several late-stage clinical programs[1][2][4].
- Therapeutic areas
- PulmonologyRheumatologyOphthalmologyEndocrinologyDermatologyNeurology
- Modalities
- Small moleculesbiologics (including monoclonal antibodies)gene therapiesother modalities across its subsidiaries
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Numerous R&D partnerships with biopharma industry players and academic institutions; specific partners not detailed in search results but known to collaborate widely on R&D solutions
04
Financials
- Market cap
- $26.5B
- Total revenue
- $8.3M
- Enterprise value
- $22.7B
Beyond the preview
Go deeper on Roivant Sciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Roivant Sciences.